Χώρα: Αρμενία
Γλώσσα: Αγγλικά
Πηγή: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
acetylcysteine
Zambon Switzerland Ltd.
R05CB01
acetylcysteine
200mg
granules for oral solution
(20) and (60) sachet 1g
OTC
Registered
2016-12-08
Core Company Data Sheet_ NACo 2015.02 20 October 2015_ 1 1. NAME OF THE MEDICINAL PRODUCT Fluimucil granules for oral solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One sachet contains 200 mg Acetylcysteine Excipient(s): For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Granules for oral solution 4. CLINICAL PARTICULARS 4 . 1 THERAPEUTIC INDICATIONS Mucolytic agent for the treatment of respiratory conditions associated with excessive mucus production 1, 2, 3, 4, 5, 6 . 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Children from 2 to 6 years of age: one 200 mg sachet twice daily. Children over 6 years of age and adults: 200 mg sachet 2-3 times daily. Method of administration No interaction with food has been reported; there is no indication regarding product administration before or after the meals. 4 . 3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Children under 2 years of age. Active peptic ulcer. Phenylketonuria. Fructose intolerance Fluimucil should not be used during breastfeeding. _With caution_ - Gastric ulcer and duodenal ulcer, esophageal varices, hemoptysis, pulmonary hemorrhage, bronchial asthma, diseases of the adrenal glands, liver and / or renal failure, hypertension. Core Company Data Sheet_ NACo 2015.02 20 October 2015_ 2 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Mucolytic agents can induce respiratory obstruction in children under 2 years of age. Due to the physiological characteristics of the airways in this age group, the ability to expectorate may be limited. Therefore mucolytic agents should not be used in children under 2 years of age (see paragraph 4.3 Contraindications). Caution is recommended when using the product in patients with peptic ulcer or history of it, especially in case of concomitant administration of other medicines with a known irritating effect on the gastric mucosa. Patients suffering from bronchial asthma must be closely monitored during therapy. Should bronchospasm occur, Διαβάστε το πλήρες έγγραφο